Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes
The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...
Diabetes
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial
Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...
AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...
Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment
The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...
Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...
Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...
Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
China Invalidates Heart Failure Patent for Dapagliflozin, Maintains Protection for Kidney Disease Use
The China National Intellectual Property Administration (CNIPA) has announced a pivotal decision concerning the patent...
Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...
Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels
Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...
Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South...
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of...